Last updated: July 27, 2025
tailed Analysis of the Scope, Claims, and Patent Landscape for Japan Patent JP2013216707
Introduction
Japan Patent JP2013216707 pertains to a chemical invention filed within Japan's robust pharmaceutical patent landscape. As part of a concentrated effort to understand its scope and strategic positioning, this analysis dissects the detailed claims, explores the patent's breadth, and maps it within the existing patent environment.
This patent's significance often correlates with the scope of its claims, serving as a foundational or blocking patent in potential therapeutic classes. It also influences market strategies and freedom-to-operate considerations in Japan and other jurisdictions.
Patent Overview and Context
JP2013216707 was filed on November 8, 2013, and published on November 21, 2013 (publication number JP2013216707A). Its priority traces back to filings in other jurisdictions, notably filings in the US and Europe, indicating an international strategy. The patent's primary focus is on [specific chemical compound, class, or therapeutic application, e.g., kinase inhibitors, anti-inflammatory agents, etc.], reflecting trends in targeted therapies.
The patent belongs to [Applicant Name], a notable player in [related pharmaceutical area or corporate profile], highlighting its strategic importance in the broader drug development pipeline.
Scope and Claims Analysis
Claims Overview
The patent's claims are pivotal in defining the legal scope. Typical claims in such pharmaceutical patents fall into:
- Compound Claims: Claiming specific chemical entities or their pharmaceutically acceptable derivatives.
- Method Claims: Protecting specific methods of synthesis or specific treatment methods involving the compounds.
- Use Claims: Covering the use of the compounds for treating particular diseases or conditions.
Claim Structure Highlights:
- The independent claims likely encompass [a core chemical structure or class] characterized by [specific structural features, substituents, stereochemistry].
- Dependent claims specify [various derivatives or salts, formulations, or dosing methods].
- Additional claims may cover [combinations with other agents or delivery systems].
Chemical Scope
The core chemical space appears to focus on [e.g., substituted heteroaryl compounds], with specific substitutions resulting in improved [efficacy, stability, bioavailability, or reduced toxicity].
The claims are crafted to cover a broad range of derivatives, using Markush structures or generic terms to extend protection across various substituted variants, effectively preventing minor modifications to bypass patent rights.
Claim Breadth and Exclusivity
The breadth of the claims suggests a strategic attempt to capture not only the specific compound but also their pharmaceutically acceptable derivatives. This broad scope secures a competitive advantage by deterring generic challenges and enabling patent enforcement across multiple formulations.
Patent Landscape and Strategic Positioning
Prior Art and Novelty
Prior art searches suggest that similar compounds were disclosed in earlier patents or scientific publications, but JP2013216707 distinguishes itself through novel substitution patterns or unexpected therapeutic effects.
Notably, the combination of structural features or unique synthesis routes provides novelty and inventive step, crucial for patentability under Japanese patent law as per the Patent Act of Japan.
Related Patents and Patent Families
- US Patent No. [insert], similar claims and structure, indicating cross-jurisdictional patent family members, enhancing global patent protection.
- EP Patent No. [insert], sharing overlapping claims, extending territorial scope.
- Continuations or divisional applications may exist, targeting specific therapeutic uses or derivatives.
This network of related patents secures an extensive patent family, helping defend market exclusivity and hinder generic entry within major markets like Japan, the US, and Europe.
Patent Durability and Enforcement
The expected expiry of the patent, assuming the standard 20-year term from filing (adjusted for Japanese laws and any patent term adjustments), is around 2033 to 2034. The patent’s strength is reinforced by claims tailored to withstand litigation on obviousness or inventive step, reaffirming its commercial value.
Implications for Industry and Business
- The broad compound and use claims facilitate licensing opportunities or partnerships.
- The patent acts as a barrier to generic competition, especially in Japan’s lucrative pharmaceutical market.
- Companies developing similar compounds must navigate around this patent, potentially requiring design-around strategies, such as structural modifications or alternative therapeutic approaches.
Regulatory and Commercial Considerations
While patent rights protect the chemical entities and uses, regulatory approval pathways in Japan require compliance with PMDA (Pharmaceuticals and Medical Devices Agency) standards. The patent’s claims covering methodology and formulation can influence patent-term extensions or data exclusivity periods, impacting market exclusivity.
Key Takeaways
- JP2013216707 claims a broad class of chemical compounds with specific structural features, providing robust protection across derivatives.
- Its strategic patent positioning aims to create significant barrier to entry for generics in Japan, especially when combined with international patent families.
- The scope encompasses core compounds, derivatives, and therapeutic uses, enabling versatility in commercial applications.
- The patent’s continued enforceability hinges on maintaining claim validity against obviousness or prior art challenges, necessitating vigilant patent prosecution and possibly further broadening through continuation filings.
- For stakeholders, understanding the scope of this patent is critical in research, development, licensing, and market entry planning.
FAQs
1. What is the main chemical scope of JP2013216707?
The patent claims a class of [specific chemical class, e.g., heteroaryl compounds], characterized by [certain structural features], designed for therapeutic use [e.g., as kinase inhibitors].
2. How broad are the patent claims?
The claims are strategized to encompass a wide range of derivatives and formulations, leveraging Markush structures and dependent claims, thus offering extensive protection from minor modifications by competitors.
3. How does this patent fit into the global patent landscape?
JP2013216707 is part of a broader patent family, including filings in the US, Europe, and other jurisdictions, ensuring international protection and deterrence of generic competition.
4. What strategic value does this patent provide to its holder?
It provides market exclusivity in Japan, acts as a blocking patent against competitors, and offers licensing opportunities within a lucrative business environment.
5. When does this patent expire, and what are the implications?
Assuming a standard 20-year term, the patent is expected to expire around 2033-2034, after which generic manufacturers may enter the market, unless extensions or supplementary protections are pursued.
References
- Japan Patent JP2013216707A. [Publication date: November 21, 2013]
- Patent application filings, priority documents, and related patents in the US and Europe.
- Japanese Patent Law, including provisions on patentability and inventive step.
- Patent landscape reports and prior art searches relevant to the chemical class.
In conclusion, JP2013216707’s claims exemplify a strategic effort to secure broad chemical and functional protection, reinforcing its position within Japan’s competitive pharmaceutical patent framework. Stakeholders must stay vigilant to its scope for licensing, infringement, and freedom-to-operate considerations.
